Serial Analysis of Fetal DNA Concentrations in Mater- nal Plasma in Late Pregnancy, Lisa Y.S. Chan, 1 Tse N.

1. Tang K, Ngoi SM, Gwee PC, Chua JMZ, Lee EJD, Chong SC, et al. Distincthaplotype profiles and strong linkage disequilibrium at the MDR1 multidrugtransporter gene locus in three ethnic Asian populations. Pharmacogenetics2002;12:437–50.2. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al.Functional polymorphisms of the human multidrug-resistance gene: multiplesequence variations and correlation of one allele with P-glycoprotein expres-sion and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473–8.3. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al.Identification of functionally variant MDR1 alleles among European Ameri-cans and African Americans. Clin Pharmacol Ther 2001;70:189–99.4. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, etal. MDR1 genotype-related pharmacokinetics of digoxin after single oraladministration in healthy Japanese subjects. Pharm Res 2001;18:1400–4.5. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al.The C3435T mutation in the human MDR1 gene is associated with alteredefflux of the P-glycoprotein substrate rhodamine 123 from CD56 naturalkiller cells. Pharmacogenetics 2001;11:293–8.6. Roberts R, Joyce P, Mulder R, Begg E, Kennedy M. A common P-glycoproteinpolymorphism is associated with nortriptyline-induced postural hypotensionin patients treated with major depression. Pharmacogenomics J 2002;2:191–6.7. Fellay J, Marzolini C, Meadon E, Back D, Buclin T, Chave J, et al. Responseto antiretroviral treatment in HIV-1-infected individuals with allelic variants ofthe multidrug resistance transporter 1: a pharmacogenetic study. Lancet2002;359:30–6.8. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression ofP-glycoprotein in human placenta: relation to genetic polymorphism of themultidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137–43.9. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, et al.Expression polymorphism of the blood-brain barrier component P-glycopro-tein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics 2002;12:529–34.10. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. Noinfluence of the MDR-1 C3435T polymorphism or a CYP3A4 promoterpolymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A troughconcentrations or rejection incidence in stable renal transplant recipients.Clin Chem 2001;47:1048–52.11. Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 geneand cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit2002;24:400–4.